A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.
about
Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney diseaseEndothelinTreatment of hypertension in obese patients.Bioimpedance spectroscopy for the estimation of body fluid volumes in miceRenal denervation after Symplicity HTN-3: an updateCombined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension.Emerging drugs for chronic kidney disease.Benefits from treatment and control of patients with resistant hypertension.Common secondary causes of resistant hypertension and rational for treatmentRole of the kidneys in resistant hypertensionHypertension Treatment for Patients with Advanced Chronic Kidney Disease.Predictors of blood pressure response in the SYMPLICITY HTN-3 trialHypertension: How should data from SYMPLICITY HTN-3 be interpreted?Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism.Endothelin and the podocyteDifferential Impact of Stress Reduction Programs upon Ambulatory Blood Pressure among African American Adolescents: Influences of Endothelin-1 Gene and Chronic Stress Exposure.Regulation of blood pressure and salt homeostasis by endothelin.TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 RatsObesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction.ET-1 actions in the kidney: evidence for sex differences.Endothelin, sex, and pregnancy: unique considerations for blood pressure control in females.Endothelium-derived endothelin-1Physiology of endothelin in producing myocardial perfusion heterogeneity: a mechanistic study using darusentan and positron emission tomography.Endothelin, kidney disease, and hypertension.Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature.High salt-induced hypertension in B2 knockout mice is corrected by the ETA antagonist, A127722Physiology of endothelin and the kidney.Update on newer antihypertensive medicines and interventions.Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice.Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension.Blood pressure control in resistant hypertension: new therapeutic options.Drug therapy for resistant hypertension: simplifying the approach.Resistant hypertension: concepts and approach to management.Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.Evaluation and pharmacologic approach to patients with resistant hypertension.Key advances in antihypertensive treatment.Renal denervation and treatment of hypertension.Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications.The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review.
P2860
Q26752292-D50EF229-D641-4103-B001-F3949883F509Q26767156-13FB3FE5-DE4D-4332-A504-4D3C5ECF7998Q30429298-7235FEFA-3E82-4709-A438-FC534AF850DAQ33995127-5F048B99-655A-4511-8CE1-F8421D66FF86Q34006930-53B686CE-41FA-4AF4-9EF8-4D6024AF5020Q34360718-833529FE-A72E-4679-A310-7E28CE84F2F0Q34384580-F208A38B-76CC-4B84-B74B-BC6D35759B44Q34420383-2850E97B-4B02-41CB-942D-81E7180934DBQ34460638-50B2D4CE-8E8C-4B03-8614-7D60046C40CEQ34669789-0B7645AC-2FE9-4107-AFAD-3DA3B014DB54Q34725369-FC1766EF-07DD-4BB2-B832-F284E1826792Q34763214-993972E5-7801-4226-814F-667101E86D7EQ34994094-FCF9C14D-959F-4E92-8D47-99C95C3AFC8CQ35170709-0F6892E6-B6FF-499D-B0F6-EBDF108F1CC5Q35354175-144AA925-4F89-4EA9-9C3F-0E7F7675A9A5Q35452282-46FD3A47-1E60-4323-946A-59AA6126208FQ35582485-D3B04B32-C1EF-451B-8CEE-3F7E2B33863DQ35609851-4071F93D-E2AC-4154-9E80-CC967A9B1E19Q35660077-5AE8A057-DF72-468B-B28D-B3B1878E8D82Q35859738-D1860546-A785-4251-AFD9-9FDD4E92E3A4Q36610325-29DCF711-9973-4DFD-9865-E42F59001A34Q36902613-66EA78D4-598C-4FA9-96A3-1A4F85C8B63DQ36958421-84D5B60D-78D4-4D7C-93BE-566E0332788DQ37187667-680C397E-D08D-4B0E-90B6-A3E7740EC1DFQ37244292-D5DBBE75-7215-4E70-91FF-38D69D6FE5D3Q37294341-6B635A65-3C69-49C7-A324-C5E51C815547Q37327363-8BDB29B5-A485-46C9-93A3-7B9FED709FC6Q37613679-204F783D-4DA1-40AF-ADAD-204D730A84BFQ37753547-CC65EF69-C1AB-41AD-91B7-5B074ADC525EQ37763199-4728ED9A-CF2F-4D89-BD03-2B9D3B6FA72BQ37775819-3FEECD7A-3604-4B03-8C19-EB0A6488014CQ37810910-DEDAFB45-4143-49EE-B5E7-0858B5926B45Q37832774-74D6EC5D-F0A0-40B6-9DDE-64A5C585244FQ37933093-68DA40BC-1EEE-48A9-8906-CE70F2C88661Q37939427-70C7605B-589E-4214-98C6-876BC190CF65Q37982211-E47690A8-FD4D-4BAC-93CE-2EDA11B5FD56Q37995074-15261B47-E343-4281-A882-041D6F464871Q38016452-436BC94A-FEB2-4276-8F97-D396B904DF86Q38016491-1F3A38AC-4F19-4159-AB76-46B14B28F8ECQ38050872-E75C18D4-30FC-4508-88B2-6164C15E3BD3
P2860
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A selective endothelin-recepto ...... ind, placebo-controlled trial.
@en
A selective endothelin-recepto ...... ind, placebo-controlled trial.
@nl
type
label
A selective endothelin-recepto ...... ind, placebo-controlled trial.
@en
A selective endothelin-recepto ...... ind, placebo-controlled trial.
@nl
prefLabel
A selective endothelin-recepto ...... ind, placebo-controlled trial.
@en
A selective endothelin-recepto ...... ind, placebo-controlled trial.
@nl
P2093
P1433
P1476
A selective endothelin-recepto ...... ind, placebo-controlled trial.
@en
P2093
Brian L Wiens
George Bakris
Henry Black
Jennifer V Linseman
Lars H Lindholm
Marshelle S Warren
Michael A Weber
Robert Weiss
Stuart Linas
P304
P356
10.1016/S0140-6736(09)61500-2
P407
P50
P577
2009-09-11T00:00:00Z